NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
TechNavio's analysts have conducted a survey on Impact of Patent Expiration on Key Drugs Categories for 2012-2016. The survey assessed the Impact of Patent Expiration on several key drugs categories such as Antipsychotic drugs, Antibiotics, ADHD drugs, Antacid drugs, Antiplatelet drugs, Asthma drugs, Diabetes drugs, Arthritis drugs, HIV drugs, Epilepsy drugs, and Cardiovascular drugs. The survey also covers the strategies adopted before patent expiration, strategies adopted to counter patent expirations, organizational impacts, and their sales impacts. Based on the overall factors, the impact of patent expiration on key drugs categories was studied for the period 2012-2016.TechNavio's report, Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report, has been prepared based on responses from over 200 participants across patented drug manufacturers, generic drug manufacturers, and a combination of both. The survey participants were selected from more than 15 top countries in the Global Pharmaceuticals market. The vendors mentioned in the report are ABX GmbH, Ache Laboratorios SA, ACI Limited, Ajanta Pharma Ltd., Alphapharm Pty Ltd., AstraZeneca Europe, AstraZeneca India, Astrazeneca do Brasil LTDA, Baxter Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, CCL Pharmaceuticals Pvt. Ltd., Cipla Ltd., Covidien India Healthcare Limited, Dr Reddy's Laboratories Ltd., Eurofarma Laboratories Ltd., Ferring Pharmaceuticals, Genus Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Healthcare Pharmaceuticals Ltd., Hospira Australia Pty Ltd., iNova Pharmaceuticals, LEO Pharma, Medley Pharmaceuticals Ltd., Merck Sharp & Dohme, MSD Pharmaceuticals Pvt. Ltd., Novartis International AG, Novartis de Colombia, Novartis farma Italy, Panacea Biotec Ltd., Pfizer Inc., PharmOut Pty Ltd., APP Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sandoz GmbH, Sandoz India Pvt Ltd., Sanofi SA, Schwabe Pharmaceuticals, Torrent Pharma, Vifor Pharma Ltd., Wanbury Ltd, and Wockhardt Ltd. Key questions answered in this report: What will the market size be in 2016 and what will the growth rate be?